• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2018 Fiscal Year Final Research Report

Development of novel and safe immune therapy to achieve hepatitis B

Research Project

  • PDF
Project/Area Number 16H05288
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Gastroenterology
Research InstitutionNagoya City University

Principal Investigator

TANAKA Yasuhito  名古屋市立大学, 大学院医学研究科, 教授 (90336694)

Co-Investigator(Kenkyū-buntansha) 岸 裕幸  富山大学, 大学院医学薬学研究部(医学), 教授 (60186210)
Research Collaborator ISOGAWA masanori  
SATO yusuke  
Project Period (FY) 2016-04-01 – 2019-03-31
KeywordsHBV / B細胞応答 / 抗ウイルス療法 / 新規免疫治療法
Outline of Final Research Achievements

Persistent infection with hepatitis B virus (HBV) causes cirrhosis・hepatocellular carcinoma as well as HBV reactivation, and its termination is urgently needed. Here, we attempted the production and optimization of humanized anti-CD40 antibody that possesses an anti-virus effect. We first evaluated the impact of CD40 activation on HBV-specific T cell receptor transgenic CD8+ T cells that were adoptively transferred into HBV transgenic mice. We found that treatment of HBV transgenic mice with CD40 antibody during the early phase of T cell responses restored functionally of HBV-specific CD8+ T cells and reduced HBV-mRNA expression levels, while the same treatment during the late phase had no impact on these parameters. We also established an ELISPOT assay system that enables us to analyze HBsAg-specific B cell responses in the human peripheral blood.

Free Research Field

消化器内科学

Academic Significance and Societal Importance of the Research Achievements

現在、HBV持続感染を治癒する有効な治療法はなく、HBV持続感染患者への精神的・経済的な負担は計り知れない。HBVの排除には宿主免疫応答の活性化が必須とされているが、最適なアプローチは全く明らかにされていない。本研究成果から、CD40抗体の投与による免疫賦活効果はHBV特異的CD8+T細胞の分化段階に依存することが明らかになった。さらに、本研究で構築したHBsAg特異的B細胞応答の解析システムにより、CD40抗体などの免疫賦活がB細胞応答に及ぼす影響をより正確に評価できるようになった。これらの結果はHBVに対する免疫治療開発を促進し、HBV持続感染による社会的負担の軽減につながると考えられる。

URL: 

Published: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi